Funded Projects › H2020
iNANOVAC4CANCER · BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY
The innovation of the biohybrid and biodegradable nanovaccines to be taken to proof-of-concept lies in the combination of different parts of the nanovaccine. A biohybrid and biodegradable nanovaccine shows potential to: (i) enhance cancer treatment efficacy; (ii) to be universally applicable to all cancers, regardless of the tumour in question; (iii) prolonging the survival rate of cancer patients; (iv) increase the amount of complete tumor remissions; and (v) boost of tumor-specific immune responses. This will allow in the future towards a personalized patient cancer therapy/treatment. More importantly, the applicability of biohybrid and biodegradable nanovaccines extends beyond the cancer treatment, as it can be applied for other type of diseases.
Consortium · 1 organisation
HELSINGIN YLIOPISTO
FI · €150,000
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.